Evidence map›Paper›PMID 40375342›Full record

ArticleBreast cancer research : BCR2025

Depression, antidepressant use, and breast cancer incidence in the Sister Study cohort.

Mary V Díaz-Santana, Jihye Park, Molly Rogers, Katie M O'Brien, Hazel B Nichols, Aimee A D'Aloisio, Deborah B Bookwalter, Dale P Sandler, Clarice R Weinberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mary V Díaz-SantanaBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Dr., Durham, NC, 27709, USA. mary.diazsantana@nih.gov.
Jihye ParkEpidemiology, Global Regulatory, Safety & Quality, GSK, Collegeville, PA, USA.
Molly RogersBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Dr., Durham, NC, 27709, USA.
Katie M O'BrienEpidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Durham, NC, USA, 27709.
Hazel B NicholsDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC, USA.
Aimee A D'AloisioSocial and Scientific Systems, Inc, 4505 Emperor Blvd, Suite 400, Durham, NC, USA.
Deborah B BookwalterWestat, 1600 Research Blvd, Rockville, MD, USA.
Dale P Sandler *Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, Durham, NC, USA, 27709.
Clarice R Weinberg *Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Dr., Durham, NC, 27709, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression could affect breast cancer risk; however, epidemiologic findings are mixed. We assessed the association of breast cancer risk with self-reported history of diagnosed depression and time-dependent antidepressant use.

methodsWe analyzed data from 45,746 women in the Sister Study cohort (2003-2009). Cox proportional hazard regression was used to estimate hazard ratios (HR) for breast cancer.

resultsDuring follow-up (mean = 11.7 years), 3,899 breast cancers were diagnosed. There was no association between history of diagnosed depression and risk of breast cancer (HR = 0.98, 95%CI = 0.91-1.06). However, antidepressant use was associated with reduced risk of breast cancer (HR = 0.92, 95%CI = 0.85-1.00). Comparison of antidepressant drug classes revealed a suggestion of an inverse association with selective serotonin reuptake inhibitors (SSRIs, HR = 0.90, 95%CI = 0.81-1.00). Reduction was stronger in those with BMI < 25 (HR = 0.72, 95%CI = 0.59-0.89).

conclusionsDepression was not associated with breast cancer risk. We observed a suggestion of a reduction in risk associated with antidepressant use. The analysis evaluating the association by specific drug types, showed a suggestion of a reduction in breast cancer risk associated with use of SSRIs. The negative association with overall antidepressant use and SSRIs, was stronger in those with BMI < 25, which could reflect a dose effect. This was the first study to examine the association between depression, antidepressant use, and breast cancer risk in a large genetic-risk-enriched cohort.

Indexed as

Antidepressive AgentsBreast NeoplasmsDepressionAdultAgedCohort StudiesFemaleHumansIncidenceMiddle AgedProportional Hazards ModelsRisk FactorsSelective Serotonin Reuptake InhibitorsAntidepressive AgentsSelective Serotonin Reuptake InhibitorsAntidepressant drugsAntidepressive AgentsBreastBreast NeoplasmsDepressionDepressive disorderOverweightSelective Serotonin Reuptake Inhibitors

Identifiers

PMID40375342
PMCPMC12083028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.